ECRG2 enhances the anti-cancer effects of cisplatin in cisplatin-resistant esophageal cancer cells via upregulation of p53 and downregulation of PCNA

Figure 5 Effects of esophageal cancer-related gene 2 and cisplatin (DDP) on the expression of proliferating cell nuclear antigen, p53, and metallothionein mRNA. I: Drug-resistant cell group; II: DDP group; III: DDP + esophageal cancer-related gene 2 (ECRG2) group. Data were expressed as the mean ± SD, n = 3. ^aP < 0.05 vs control; ^cP < 0.05 vs control; ^eP < 0.05 vs DDP groups.